Identification of the human liver cytochrome p450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor

Drug Metabolism and Disposition

Volumn 26, Issue 10, 1998, Pages 970-976

  Machinist, Joseph M ^b   Mayer, Michael D ^c   Roberts, Ellen M ^c   Surber, Bruce W ^c   Rodrigues, A David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [5 (4 FLUOROBENZYL) 2 THIENYL] 1 METHYL 2 PROPYNYL]UREA; ATRELEUTON; CYTOCHROME P450; KETOCONAZOLE; LIPOXYGENASE INHIBITOR; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL;

ARACHIDONATE 5-LIPOXYGENASE; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; FLUOROBENZENES; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MICROSOMES, LIVER; THIOPHENES;

EID: 0031724342     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR and Dubè LM (1995a) The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclooxygenase inhibitor naproxen in human volunteers Clin Pharmacokinet 29(Suppl 2):112-124.
2. Awni WM, Cavanaugh JH, Tzeng T-B, Witt G, Granneman GR and Dubè LM (1995b) Pharmacokinetic interactions between zileuton and prednisone. Clin Pharmacokinet 29(Suppl 2):105-111.
3. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dubè LM and Cavanaugh JH (1995c) Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 29(Suppl 2):67-76.
4. Brooks DW, Bell RL, Carter GW and Dubè LM (1993) Zileuton. Drugs Future 18:616-618.
5. Brooks CDW, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C, Harris RR, Malo PE, Carter GW and Bell RL (1995) (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]1-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J Med Chem 38:4768-4775.
6. Campbell ME, Grant DM, Tadanobu I and Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15:237-249.
7. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB and Brooks DW (1991) 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256:929-937.
8. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y and Staib AH (1992) Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P-450 isoforms. Biochem Pharmacol 43:225-235.
9. Granneman GR, Braeckman R, Locke C, Cavanaugh J, Awni WM and Dubè L (1995) Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 29(Suppl 2):77-83.
10. Gu L, Gonzalez FJ, Kalow W and Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77.
11. Guengerich FP (1995) Cytochrome P450 of human liver: classification and activity profiles of the major enzymes, in Advances in Drug Metabolism in Man (Pacifici GM and Fraccia GN eds) pp 181-231, European Commission, Brussels.
12. Isreal E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P and Drazen JM (1990) The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 323:1740-1744.
13. Lecoeur S, Bonierbale E, Challine D, Gautier J-C, Valadon P, Dansette PM, Catinot R, Ballet F, Mansuy D and Beaune PH (1994) Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res Toxicol 7:434-442.
14. Machinist JM, Mayer MD, Shet MS, Ferrero JL and Rodrigues AD (1995) Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite Abbott-66193. Drug Metab Dispos 23:1163-1174.
15. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 23:2370-2378.
16. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P4502C in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
17. Rodrigues AD (1994) Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem Pharmacol 48:197-200.
18. 14C]Naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126-136.
19. 14C]dextromethorphan. Anal Biochem 219:309-320.
20. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
21. Rosenberg MA, Torres MJ, Valencia A, Garcia JJ, Miranda A, Drajesk JF, Brandwein S, Lanni C and Blanca M (1995) The effect of a 5-lipoxygenase (5-LO) inhibitor, ABT-761, on inhaled house dust mite early asthmatic response. J Allergy Clin Immunol 95:352, Abstract No. 845.
22. Samara E, Cavanaugh JH, Mukherjee D and Granneman GR (1995) Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin Pharmacokinet 29(Suppl 2):84-91.
23. Sarkar MA, Hunt C, Guzelian PS and Karnes HT (1992) Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 20:31-37.
24. Schwab GE, Raucy JL and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol 33:493-499.
25. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ and Guengerich FP (1989) Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res 49:6304-6312.
26. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
27. Vree TB, Van Den Biggelaar-Martea M, Veerwey-Van Wisen CPGM, Vree ML and Guelen PJM (1993) The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans: effect of cimetidine. Br J Clin Pharmacol 35:467-472.
28. Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P and Sperling R (1992) Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 19:1537-1541.
29. Wong SL, Cavanaugh JH, Qian J, Hansen R and Awni WM (1998) Effect of ABT-761 on the pharmacokinetics of theophylline. Clin Pharmacol Ther, in press.
30. Zhang Z, Fasco MJ, Huang Z, Guengerich FP and Kaminsky LS (1995) Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 23:1339-1345.